Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

A Phase 2 clinical trial testing Galápagos‘ experimental oral therapy GLPG3667 in people with systemic lupus erythematosus (SLE) has failed to meet its main goal, although some promising trends were ...

Seattle Children’s has been cleared by the U.S. Food and Drug Administration (FDA) to start the nation’s first clinical trial testing CAR T-cell therapy in children with systemic lupus erythematosus, ...

Once you receive a diagnosis of lupus, it is difficult to avoid its chronic impact. The disease stays on your mind and affects your perceptions and decisions. You may not be in a flare or “suffering,” ...

Patient screening is underway in a U.S.-based clinical trial of NKX019, an investigational natural killer (NK) cell therapy for people with treatment-resistant lupus nephritis, a serious complication ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...

Holidays are either the best or the absolute worst time to get out and travel. Yes, there’s the joy of seeing extended family, sharing gifts, laughing through photo albums, reuniting with old friends ...

Ventus Therapeutics plans to develop a new treatment candidate for lupus and other inflammatory diseases marked by the activation of the type 1 interferon immune system pathway, the company recently ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, a form of lupus marked by kidney damage. Lupus is an autoimmune ...

Lupus Therapeutics is collaborating with Artiva Biotherapeutics on a Phase 1 clinical trial testing AlloNK, a natural killer (NK) cell therapy candidate, in patients with lupus nephritis, which is one ...

A team led by researchers at the Hospital for Special Surgery (HSS) Research Institute has been given two grants to investigate the potential causes of lupus flares. The research team will focus on ...